Its worth noting that the EMA has sanctioned use for all age groups, and has agreed with MHRA's assessment that, although there is limited data on efficacy in older groups, all the other data such as immune response suggest it should have a similar efficacy to other age groups, and as it is clearly safe to use, there are no reasons not to use it:Saint wrote: Wed Feb 03, 2021 9:34 amdpedin wrote: Wed Feb 03, 2021 9:24 amThis is fantastic news and offers a route out of this shitstorm. However we need to be using this time to get TTT up to speed, put in place better support for those asked to isolate and properly close borders to avoid importing dodgy mutations. Whilst out track record in vaccination development and roll out - thanks to scientists and NHS - is top class out record in these other three essentials has been awful and need to radically improve. I would begin to start efforts to shift TTT to the NHS and PH experts and establish the local systems based around NHS/Councils we should have had in the first place, including sacking the failed TalkTalk CEO and Jockey Club Director Dido.Lobby wrote: Tue Feb 02, 2021 8:35 pm
And yet in Europe, Germany, France and Sweden won’t use it for anyone over 65; Poland won’t use it for anyone over 60; and Italy won’t use it for anyone over 55. At their current rate of vaccination, I’m not sure they’ll actually need any AZ doses until the Autumn.
I thought the EU countries didnt say they wouldn't use it but were concerned there were only small numbers of older people involved in the stage 3 trials and were waiting for more data before sanctioning its use in older people. The UK took a calculated gamble, which based on other vaccines was a pretty good bet, in using it in older people and in extending the interval between 1st and 2nd dose to 12 weeks even though the evidence from the trials was incomplete. Our gamble has paid off and perhaps the EU and their regulators were just more risk averse in this case. However as the evidence emerges, primarily from the UK gamble, they will agree its use in older people very very soon.
I would be fairly certain the MHRA has had access to all of the data in this study as part of their rolling review with AZ and their general partnership with Oxford for some time - hence why some decisions were made the way they were
“There were not enough results in older participants (over 55 years old) to provide a figure for how well the vaccine will work in this group. However, protection is expected, given that an immune response is seen in this age group and based on experience with other vaccines; as there is reliable information on safety in this population, EMA’s scientific experts considered that the vaccine can be used in older adults.”
At the moment, the decision of several EU states to ignore the EMA's advice and not use the AZ vaccine for older people looks more like an expression of their current discontent with AZ.